생물학적 표적 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "생물학적 표적" in Korean language version.

refsWebsite

Global rank Korean rank

14doi.org

2^nd place

3^rd place

13nih.gov

4^th place

5semanticscholar.org

11^th place

310^th place

4harvard.edu

18^th place

27^th place

1archive.org

6^th place

18^th place

1inkling.com

low place

archive.org

Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G (2012). 〈Chapter 3: How drugs act: molecular aspects〉. 《Rang and Dale's Pharmacology》. Edinburgh; New York: Elsevier/Churchill Livingstone. 20–48쪽. ISBN 978-0-7020-3471-8.

doi.org

dx.doi.org

Raffa RB, Porreca F (1989). “Thermodynamic analysis of the drug-receptor interaction”. 《Life Sciences》 44 (4): 245–58. doi:10.1016/0024-3205(89)90182-3. PMID 2536880.
Moy VT, Florin EL, Gaub HE (October 1994). “Intermolecular forces and energies between ligands and receptors”. 《Science》 266 (5183): 257–9. Bibcode:1994Sci...266..257M. doi:10.1126/science.7939660. PMID 7939660.
Overington JP, Al-Lazikani B, Hopkins AL (December 2006). “How many drug targets are there?”. 《Nature Reviews. Drug Discovery》 5 (12): 993–6. doi:10.1038/nrd2199. PMID 17139284. S2CID 11979420.
Landry Y, Gies JP (February 2008). “Drugs and their molecular targets: an updated overview”. 《Fundamental & Clinical Pharmacology》 22 (1): 1–18. doi:10.1111/j.1472-8206.2007.00548.x. PMID 18251718. S2CID 205630866.
Lundstrom K (2009). 〈An overview on GPCRs and drug discovery: structure-based drug design and structural biology on GPCRs〉. 《G Protein-Coupled Receptors in Drug Discovery》. Methods in Molecular Biology 552. 51–66쪽. doi:10.1007/978-1-60327-317-6_4. ISBN 978-1-60327-316-9. PMC 7122359. PMID 19513641.
Dixon SJ, Stockwell BR (December 2009). “Identifying druggable disease-modifying gene products”. 《Current Opinion in Chemical Biology》 13 (5–6): 549–55. doi:10.1016/j.cbpa.2009.08.003. PMC 2787993. PMID 19740696.
Lee H, Lee JW (2016). “Target identification for biologically active small molecules using chemical biology approaches”. 《Archives of Pharmacal Research》 39 (9): 1193–201. doi:10.1007/s12272-016-0791-z. PMID 27387321. S2CID 13577563.
Lomenick B, Olsen RW, Huang J (January 2011). “Identification of direct protein targets of small molecules”. 《ACS Chemical Biology》 6 (1): 34–46. doi:10.1021/cb100294v. PMC 3031183. PMID 21077692.
Jung HJ, Kwon HJ (2015). “Target deconvolution of bioactive small molecules: the heart of chemical biology and drug discovery”. 《Archives of Pharmacal Research》 38 (9): 1627–41. doi:10.1007/s12272-015-0618-3. PMID 26040984. S2CID 2399601.
Moffat JG, Vincent F, Lee JA, Eder J, Prunotto M (2017). “Opportunities and challenges in phenotypic drug discovery: an industry perspective”. 《Nature Reviews. Drug Discovery》 16 (8): 531–543. doi:10.1038/nrd.2017.111. PMID 28685762. S2CID 6180139. Novelty of target and MoA [Mechanism of Action] is the second major potential advantage of PDD [Phenotypic Drug Discovery]. In addition to identifying novel targets, PDD can contribute to improvements over existing therapies by identifying novel physiology for a known target, exploring 'undrugged' targets that belong to well known drug target classes or discovering novel MoAs, including new ways of interfering with difficult-to-drug targets.
Gunnarsson L, Jauhiainen A, Kristiansson E, Nerman O, Larsson DG (August 2008). “Evolutionary conservation of human drug targets in organisms used for environmental risk assessments”. 《Environmental Science & Technology》 42 (15): 5807–5813. Bibcode:2008EnST...42.5807G. doi:10.1021/es8005173. PMID 18754513.
Larsson DG, Adolfsson-Erici M, Parkkonen J, Pettersson M, Berg AM, Olsson PE, Förlin L (April 1999). “Ethinyloestradiol — an undesired fish contraceptive?”. 《Aquatic Toxicology》 45 (2–3): 91–97. doi:10.1016/S0166-445X(98)00112-X.
Ankley GT, Brooks BW, Huggett DB, Sumpter JP (2007). “Repeating history: pharmaceuticals in the environment”. 《Environmental Science & Technology》 41 (24): 8211–7. Bibcode:2007EnST...41.8211A. doi:10.1021/es072658j. PMID 18200843.
Kostich MS, Lazorchak JM (2008). “Risks to aquatic organisms posed by human pharmaceutical use”. 《The Science of the Total Environment》 389 (2–3): 329–39. Bibcode:2008ScTEn.389..329K. doi:10.1016/j.scitotenv.2007.09.008. PMID 17936335.

harvard.edu

adsabs.harvard.edu

Moy VT, Florin EL, Gaub HE (October 1994). “Intermolecular forces and energies between ligands and receptors”. 《Science》 266 (5183): 257–9. Bibcode:1994Sci...266..257M. doi:10.1126/science.7939660. PMID 7939660.
Gunnarsson L, Jauhiainen A, Kristiansson E, Nerman O, Larsson DG (August 2008). “Evolutionary conservation of human drug targets in organisms used for environmental risk assessments”. 《Environmental Science & Technology》 42 (15): 5807–5813. Bibcode:2008EnST...42.5807G. doi:10.1021/es8005173. PMID 18754513.
Ankley GT, Brooks BW, Huggett DB, Sumpter JP (2007). “Repeating history: pharmaceuticals in the environment”. 《Environmental Science & Technology》 41 (24): 8211–7. Bibcode:2007EnST...41.8211A. doi:10.1021/es072658j. PMID 18200843.
Kostich MS, Lazorchak JM (2008). “Risks to aquatic organisms posed by human pharmaceutical use”. 《The Science of the Total Environment》 389 (2–3): 329–39. Bibcode:2008ScTEn.389..329K. doi:10.1016/j.scitotenv.2007.09.008. PMID 17936335.

inkling.com

Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G (2012). 〈Chapter 2: How drugs act: general principles〉. 《Rang and Dale's Pharmacology》. Edinburgh; New York: Elsevier/Churchill Livingstone. 6–19쪽. ISBN 978-0-7020-3471-8.

nih.gov

ncbi.nlm.nih.gov

Raffa RB, Porreca F (1989). “Thermodynamic analysis of the drug-receptor interaction”. 《Life Sciences》 44 (4): 245–58. doi:10.1016/0024-3205(89)90182-3. PMID 2536880.
Moy VT, Florin EL, Gaub HE (October 1994). “Intermolecular forces and energies between ligands and receptors”. 《Science》 266 (5183): 257–9. Bibcode:1994Sci...266..257M. doi:10.1126/science.7939660. PMID 7939660.
Overington JP, Al-Lazikani B, Hopkins AL (December 2006). “How many drug targets are there?”. 《Nature Reviews. Drug Discovery》 5 (12): 993–6. doi:10.1038/nrd2199. PMID 17139284. S2CID 11979420.
Landry Y, Gies JP (February 2008). “Drugs and their molecular targets: an updated overview”. 《Fundamental & Clinical Pharmacology》 22 (1): 1–18. doi:10.1111/j.1472-8206.2007.00548.x. PMID 18251718. S2CID 205630866.
Lundstrom K (2009). 〈An overview on GPCRs and drug discovery: structure-based drug design and structural biology on GPCRs〉. 《G Protein-Coupled Receptors in Drug Discovery》. Methods in Molecular Biology 552. 51–66쪽. doi:10.1007/978-1-60327-317-6_4. ISBN 978-1-60327-316-9. PMC 7122359. PMID 19513641.
Dixon SJ, Stockwell BR (December 2009). “Identifying druggable disease-modifying gene products”. 《Current Opinion in Chemical Biology》 13 (5–6): 549–55. doi:10.1016/j.cbpa.2009.08.003. PMC 2787993. PMID 19740696.
Lee H, Lee JW (2016). “Target identification for biologically active small molecules using chemical biology approaches”. 《Archives of Pharmacal Research》 39 (9): 1193–201. doi:10.1007/s12272-016-0791-z. PMID 27387321. S2CID 13577563.
Lomenick B, Olsen RW, Huang J (January 2011). “Identification of direct protein targets of small molecules”. 《ACS Chemical Biology》 6 (1): 34–46. doi:10.1021/cb100294v. PMC 3031183. PMID 21077692.
Jung HJ, Kwon HJ (2015). “Target deconvolution of bioactive small molecules: the heart of chemical biology and drug discovery”. 《Archives of Pharmacal Research》 38 (9): 1627–41. doi:10.1007/s12272-015-0618-3. PMID 26040984. S2CID 2399601.
Moffat JG, Vincent F, Lee JA, Eder J, Prunotto M (2017). “Opportunities and challenges in phenotypic drug discovery: an industry perspective”. 《Nature Reviews. Drug Discovery》 16 (8): 531–543. doi:10.1038/nrd.2017.111. PMID 28685762. S2CID 6180139. Novelty of target and MoA [Mechanism of Action] is the second major potential advantage of PDD [Phenotypic Drug Discovery]. In addition to identifying novel targets, PDD can contribute to improvements over existing therapies by identifying novel physiology for a known target, exploring 'undrugged' targets that belong to well known drug target classes or discovering novel MoAs, including new ways of interfering with difficult-to-drug targets.
Gunnarsson L, Jauhiainen A, Kristiansson E, Nerman O, Larsson DG (August 2008). “Evolutionary conservation of human drug targets in organisms used for environmental risk assessments”. 《Environmental Science & Technology》 42 (15): 5807–5813. Bibcode:2008EnST...42.5807G. doi:10.1021/es8005173. PMID 18754513.
Ankley GT, Brooks BW, Huggett DB, Sumpter JP (2007). “Repeating history: pharmaceuticals in the environment”. 《Environmental Science & Technology》 41 (24): 8211–7. Bibcode:2007EnST...41.8211A. doi:10.1021/es072658j. PMID 18200843.
Kostich MS, Lazorchak JM (2008). “Risks to aquatic organisms posed by human pharmaceutical use”. 《The Science of the Total Environment》 389 (2–3): 329–39. Bibcode:2008ScTEn.389..329K. doi:10.1016/j.scitotenv.2007.09.008. PMID 17936335.

semanticscholar.org

api.semanticscholar.org

Overington JP, Al-Lazikani B, Hopkins AL (December 2006). “How many drug targets are there?”. 《Nature Reviews. Drug Discovery》 5 (12): 993–6. doi:10.1038/nrd2199. PMID 17139284. S2CID 11979420.
Landry Y, Gies JP (February 2008). “Drugs and their molecular targets: an updated overview”. 《Fundamental & Clinical Pharmacology》 22 (1): 1–18. doi:10.1111/j.1472-8206.2007.00548.x. PMID 18251718. S2CID 205630866.
Lee H, Lee JW (2016). “Target identification for biologically active small molecules using chemical biology approaches”. 《Archives of Pharmacal Research》 39 (9): 1193–201. doi:10.1007/s12272-016-0791-z. PMID 27387321. S2CID 13577563.
Jung HJ, Kwon HJ (2015). “Target deconvolution of bioactive small molecules: the heart of chemical biology and drug discovery”. 《Archives of Pharmacal Research》 38 (9): 1627–41. doi:10.1007/s12272-015-0618-3. PMID 26040984. S2CID 2399601.
Moffat JG, Vincent F, Lee JA, Eder J, Prunotto M (2017). “Opportunities and challenges in phenotypic drug discovery: an industry perspective”. 《Nature Reviews. Drug Discovery》 16 (8): 531–543. doi:10.1038/nrd.2017.111. PMID 28685762. S2CID 6180139. Novelty of target and MoA [Mechanism of Action] is the second major potential advantage of PDD [Phenotypic Drug Discovery]. In addition to identifying novel targets, PDD can contribute to improvements over existing therapies by identifying novel physiology for a known target, exploring 'undrugged' targets that belong to well known drug target classes or discovering novel MoAs, including new ways of interfering with difficult-to-drug targets.